Hum. Reprod. Advance Access originally published online on December 16, 2005
Human Reproduction 2006 21(4):1070-1075; doi:10.1093/humrep/dei434
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term conservative therapy for endometrial adenocarcinoma in young women
Department of Obstetrics & Gynecology, School of Medicine, Niigata University, Niigata city, Niigata, Japan
1 To whom correspondence should be addressed at: Department of Obstetrics & Gynecology, School of Medicine, Niigata University, 1-757 Asahimachi-Dori, Niigata city, Niigata 951-8510, Japan. E-mail: yahatat{at}med.niigata-u.ac.jp
BACKGROUND: To evaluate the efficacy and safety of long-term conservative therapy with medroxyprogesterone acetate (MPA) for endometrial carcinoma in young patients who had experienced failure after initial therapy or relapse, we reviewed the clinical and pathologic records of eight patients diagnosed with well-differentiated endometrial adenocarcinoma without myometrial invasion who were treated with MPA for over 6 months because of treatment failure or relapse. RESULTS: The average duration of MPA treatment was 22 months. All patients were followed-up for a mean of 76.5 months. Seven patients responded to initial MPA treatment within a period of 14 months (mean, 7.9 months). All these patients experienced relapse and the mean time to relapse was 11.6 months (range, 4–33 months). All six patients with relapse were treated with additional treatments of MPA, and all but one responded to this treatment within a period of 16 months (mean, 8.0 months). Six patients ultimately underwent hysterectomy. All presented well-differentiated endometrioid adenocarcinomas without extrauterine disease. Three became pregnant and two delivered full-term normal infants. No patient died of the disease. CONCLUSION: Although lesions are expected to disappear with prolonged MPA treatment, this form of progestin therapy is hazardous because recurrence occurs frequently. Only strictly selected patients should therefore be indicated for long-term MPA treatment and careful evaluation before and after treatment should be performed.
Key words: conservative therapy/endometrial adenocarcinoma/medroxyprogesterone acetate
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Wang, P. Hanifi-Moghaddam, E. E. Hanekamp, H. J. Kloosterboer, P. Franken, J. Veldscholte, H. C. van Doorn, P. C. Ewing, J. J. Kim, J. A. Grootegoed, et al. Progesterone Inhibition of Wnt/{beta}-Catenin Signaling in Normal Endometrium and Endometrial Cancer Clin. Cancer Res., September 15, 2009; 15(18): 5784 - 5793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Boyd Endometrial Adenocarcinoma Journal of Diagnostic Medical Sonography, March 1, 2007; 23(2): 106 - 109. [PDF]
|
|